12/2/2021, 8:20 AM (Source: TeleTrader)
more TeleTrader news

GSK: Antibody treatment works against Omicron

GlaxoSmithKline plc said on Thursday that preclinical data showed that its COVID-19 antibody treatment sotrovimab "retains activity against key mutations of the Omicron variant."

"Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable," GSK CEO George Scangos stated.

The GSK antibody treatment has been approved in the United States and Australia and is under review in the European Union.

Baha Breaking News (BBN) / NP